Cutting-edge noninvasive detection.

To increase testing compliance by decreasing discomfort.

About

Us

Background​

Currently, there is no immediate diagnosis or combined diagnosis-treatment option for gynecologic malignancies such as cervical, ovarian, and endometrial cancers. This leaves patients vulnerable to greater health risks, including infertility, and the potential of other aggressive types of side effects or risks to quality of life. On a yearly basis there are 7.2 million new cases of cancer of the female reproductive system, of which up to 266,000 result in deaths for cervical cancer. 

Our Vision

A microneedle mediated diagnostic patch that detects early onset of cervical cancer, replacing invasive procedures such as the Pap Smear and colposcopies. The digitized medical device, is able to detect novel targets within 30-45 min. - equivalent to a clinical visit. Providing benefits to health professionals for better management of guidelines and improved patient outcomes.  

Mission

CurivaTM is committed to reducing the incidence of cervical cancer by increasing testing compliance through a non-invasive diagnostic patch. Our patient-centric products deliver accurate, same-day results while reducing diagnostic costs for healthcare providers.

 
 
EYDIS LIMA,MSc

Founder &

Chief Executive Officer

Entrepreneur | Chemical Engineer 

University of Notre Dame

  • White LinkedIn Icon
  • White Twitter Icon
PATRICIA SIGMON

Strategy Advisor

CEO

David Advisory Group

ADVISORS

Clinical Research Advisor

Vice Chair for Research, Department of Obstetrics and Gynecology

Wayne State University

*Considering additional advisors

GIL MOR, MD PHD
ELIZABETH JENNINGS

Strategy Advisor

Atlas Venture Labs

TONY RACCIO

Human Capital Advisor

Perseid Partners

YSM6416_0004_G_AltwergerCnoB_col.jpg

Co - Founder &

Chief Medical Officer

 

Yale University

Yale Cancer Center

  • White LinkedIn Icon
GARY ALTWERGER,MD

OUR TEAM

Meet the Curiva team!

ANDRE NOGALES,MBA

Chief Financial Officer

Entrepreneur | Finance 

Australian National University

  • White LinkedIn Icon

What 

We

Offer

diapatch™ screens and detects —

 

CIN II biomarkers

 

CIN III biomarkers

HPV biomarkers

 

Seamless and effortless integration into busy, modern lifestyles, allowing for streamlined, higher quality patient care during the usual women wellness visit or consult with family medicine practitioner, gynecologist, or gynecologic oncologist. 

Accurate, quick,

and noninvasive diagnosis 

diapatch™ CER  — designed with patients that have had a series of abnormal Pap Smears in mind, it provides an additional tool prior to detect and monitor disease burden prior to colposcopies.

diapatch™ HPV — supports patients wanting a non-invasive, lower anxiety option for yearly well women's exams. Not only capturing the screening market but also facilitating screening of HPV at earlier ages.

Why

Us?

Faster, more accurate diagnosis
Non-invasive approach for easier workflow and patient care
Same-day results for appropriate patient triaging, follow-up procedures, and treatment options
 

Contact

Us

Our Office

MATTER

222 W Merchandise Mart Plaza #1230, Chicago, IL 60654

Our Lab

Goshen, IN

Our Email

contactus@curiva.co

Our Phone No.

574-400-5136

Success! Message received.